<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924491</url>
  </required_header>
  <id_info>
    <org_study_id>THYTECH1-2018-005</org_study_id>
    <nct_id>NCT04924491</nct_id>
  </id_info>
  <brief_title>Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children</brief_title>
  <acronym>THYTECH</acronym>
  <official_title>Randomized, Exploratory and Prospective Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of the Transfusion of Autologous Treg Cells Obtained From Thymic Tissue in the Prevention of Rejection in Heart Transplant Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rafael Correa-Rocha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación Familia Alonso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General Universitario Gregorio Marañon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators developed a protocol to isolate Treg cells from thymic tissue (thyTreg)&#xD;
      discarded in pediatric cardiac surgeries. After completing the pre-clinical studies, the&#xD;
      investigators have initiated a phase I/II clinical trial to test the safety and efficacy of&#xD;
      the adoptive transfer of autologous thyTreg to prevent rejection in heart transplant&#xD;
      children.&#xD;
&#xD;
      Condition or disease: Heart Transplantation Intervention/treatment: Regulatory T Cell (Treg)&#xD;
      Infusion&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current transplant practice is far from guaranteeing the life expectancy of patients,&#xD;
      particularly if the patients are children. THYTECH aims to revolutionize the field of&#xD;
      clinical immunology developing a new approach to govern the regulatory skills of immune&#xD;
      system, preventing graft rejection and opening a new frontier in the treatment of immune&#xD;
      diseases.&#xD;
&#xD;
      Transfer of regulatory T cells (Treg) has acquired growing interest in the race to achieve&#xD;
      indefinite transplant survival. Up to now, the use of Treg therapy to prevent solid graft&#xD;
      rejection in humans has demonstrated that this therapy is safe, but the clinical efficacy is&#xD;
      limited. The small Treg numbers that can be purified from peripheral blood along with the low&#xD;
      survival and limited suppressive capacity of differentiated Tregs obtained from adults have&#xD;
      probably compromised the efficacy of this therapy.&#xD;
&#xD;
      The investigators have developed an innovative approach to overcome current barriers and make&#xD;
      Treg transfer a reality equipped to achieve indefinite graft survival. The major innovation&#xD;
      of THYTECH is the employment of thymic tissue, the site of Treg generation, as a new source&#xD;
      of Tregs to obtain massive amounts of thymus-derived Tregs (thyTreg) with very high purity&#xD;
      (&gt;95% of CD 25+ Foxp3+ cells) and improved survival and suppressive capacities. The&#xD;
      investigators are recruiting patients in a clinical trial transferring autologous Tregs in&#xD;
      heart-transplanted children to prevent graft rejection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Repopulation of Treg cells in the patient, determined as the increase in their blood values and the recovery of the ratio Treg / T-effector cells with respect to the values prior to transplantation.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of episodes of acute myocardial rejection (diagnosed by echocardiography) that require treatment in the 2 years post-transplant</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treg cells in peripheral blood</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of naive and memory Treg cells, and the production/levels of interferon gamma and interleukins (IL-4, IL-17A and IL-10).</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of cell subsets related with rejection (CD8 T cells subsets, activated T cells, antibody-secreting B cells) during the post-transplant follow-up period.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall patient survival rate at 24 months.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on parameters of electrocardiogram (PR, QRS and QTc interval) of transplanted heart.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on parameters of echocardiogram (mitral and tricuspid regurgitation; mitral and tissue mitral Doppler; and tricuspid and tissue tricuspid Doppler ) of transplanted heart.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by NCI-CTCAE V4.03 criteria.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Heart Transplantation</condition>
  <arm_group>
    <arm_group_label>10.000.000 thyTreg /kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous thyTreg 10.000.000</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20.000.000 thyTreg /kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous thyTreg 20.000.000</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous thyTreg</intervention_name>
    <description>Treg lymphocytic cells, differentiated, autologous, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)</description>
    <arm_group_label>10.000.000 thyTreg /kg</arm_group_label>
    <arm_group_label>20.000.000 thyTreg /kg</arm_group_label>
    <other_name>thyTreg cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient under two years of age, who meets all the necessary requirements to undergo a&#xD;
             heart transplant.&#xD;
&#xD;
          2. Patients without contraindication to immunosuppressive drugs.&#xD;
&#xD;
          3. Parents and/or guardians must be willing and able to understand the purpose and risks&#xD;
             of the study and must sign the informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with DiGeorge Syndrome, since their thymic function is affected.&#xD;
&#xD;
          2. Human immunodeficiency virus positive serology&#xD;
&#xD;
          3. Epstein-Barr virus active infection&#xD;
&#xD;
          4. Patients hyperimmunized with cytotoxic anti-human leukocyte antigen antibodies&#xD;
&#xD;
          5. Patients with a history of previous malignancy&#xD;
&#xD;
          6. Patients who have participated in other intervention studies in the last month.&#xD;
&#xD;
          7. Patients who have received induction therapy with Basiliximab or Thymoglobulin.&#xD;
&#xD;
          8. Patients who have previously been thymectomized or transplanted.&#xD;
&#xD;
          9. Patients who have been diagnosed with severe autoimmune disease (celiac disease,&#xD;
             autoimmune hypothyroidism, autoimmune diabetes)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Correa-Rocha, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Marañon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rafael Correa-Rocha, PhD</last_name>
    <phone>+34 915866455</phone>
    <email>rafael.correa@iisgm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana Hernandez Florez, PhD</last_name>
    <phone>+34 915290019</phone>
    <email>diana.hernandez@iisgm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Correa-Rocha, PhD</last_name>
      <phone>+34 915866455</phone>
      <email>rafael.correa@iisgm.com</email>
    </contact>
    <investigator>
      <last_name>Esther Bernaldo-de-Quiros, MsC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marjorie Pion, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Hernández-Flórez, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Martínez-Bonet, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuela Camino Lopez, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Miguel Gil-Jaurena, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nuria Gil Villanueva, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Pardo, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mª Eugenia Fernández-Santos, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramón Pérez-Caballero, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Universitario Gregorio Marañon</investigator_affiliation>
    <investigator_full_name>Rafael Correa-Rocha</investigator_full_name>
    <investigator_title>Group Leader</investigator_title>
  </responsible_party>
  <keyword>Cardiac Disease</keyword>
  <keyword>Regulatory T cell</keyword>
  <keyword>Immunomodulation</keyword>
  <keyword>Tolerogenic protocol</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <keyword>Immunologic Factors</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

